Navigation Links
Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
Date:3/23/2009

SAN DIEGO, March 24 /PRNewswire/ -- Calixa Therapeutics Inc. today announced positive results from a Phase 1 trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity.

The results from this first Phase 1 study demonstrated that CXA-101 was well tolerated, with a clinical and laboratory safety profile similar to that of marketed cephalosporin antibiotics. No dose-limiting toxicity was observed, even at the highest dose regimen evaluated. In addition, CXA-101 demonstrated predictable, linear pharmacokinetics after intravenous administration in humans. The results of this study fully support the further clinical development of this compound.

"Pseudomonas aeruginosa is usually less susceptible to commonly used antibiotics, and infections caused by this organism are often severe and very difficult to treat," said Ian Friedland, M.D., chief medical officer of Calixa Therapeutics. "There is a need for a safe and efficacious antibiotic to treat pseudomonal infections. Unfortunately, the pipeline for such drugs is virtually empty. The promising results in Phase 1 will enable us to quickly advance CXA-101 into Phase 2 to evaluate its safety and efficacy in patients."

The completed Phase 1 trial was designed as a single- and multiple-ascending dose study to assess the safety, tolerability and pharmacokinetic profile of the compound in healthy volunteers. The study was successfully conducted in the U.S. under an IND.

"Our development program is progressing well with our team that has a proven track record in the anti-infective field," said Eckard Weber, M.D., CEO and president of Calixa Therapeutics. "The Phase 1 data suggest a well-tolerated drug with an excellent profile for potential clinical use as a treatment of gram-negative bacterial infections."

Calixa Therapeutics acquired the global development rights (exclude certain Asia-Pacific territories) to CXA-101 (FR264205) from Astellas Pharma Inc. in 2007. CXA-101's potent in vitro activity against Pseudomonas aeruginosa has the potential to address the unmet medical need posed by this very problematic gram-negative pathogen, which is a common cause of serious infection associated with high morbidity and mortality. Nonclinical studies have shown CXA-101 is highly active against multiple drug-resistant Pseudomonas aeruginosa, including many strains resistant to carbapenems, an antibiotic class generally considered as having the most potent activity against resistant gram-negative pathogens.

About Calixa Therapeutics

Calixa Therapeutics Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of infectious diseases. The company's initial focus is on developing novel antibiotics for use in the hospital setting. Calixa Therapeutics, which is privately held, is headquartered in San Diego and has operations in the San Francisco Bay Area. For additional information, please visit: www.calixainc.com.

    Contacts:

    Robert Flamm, Ph.D., or David Schull
    Russo Partners
    (212) 845-4226
    robert.flamm@russopartnersllc.com
    david.schull@russopartnersllc.com

    Eckard Weber, M.D.
    Calixa Therapeutics Inc.
    (858) 480-2420
    stone@domainvc.com


'/>"/>
SOURCE Calixa Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
2. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
6. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
7. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
8. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
9. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
10. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
Breaking Medicine News(10 mins):